Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile

  • Rossi-Herring, Guido
  • Belmonte, Thalía
  • Rivas-Urbina, Andrea
  • Benítez, Sònia
  • Rotllan, Noemi
  • Crespo, Javier
  • Llorente-Cortés, Vicenta
  • Sánchez Quesada, Jose Luis
  • de Gonzalo Calvo, David
Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the bibliography on this topic is scarce and shows a high variability between independent investigations. In addition, the miRNA profiles of the LDL and VLDL fractions have not been completely elucidated. Here, we profiled the human circulating lipoprotein-carried miRNome. Lipoprotein fractions (VLDL, LDL and HDL) were isolated from the serum of healthy subjects by ultracentrifugation and purified by size-exclusion chromatography. A panel of 179 miRNAs commonly expressed in circulation was evaluated in the lipoprotein fractions using quantitative real-time PCR (qPCR) assays. A total of 14, 4 and 24 miRNAs were stably detected in the VLDL, LDL and HDL fractions, respectively. VLDL- and HDL-miRNA signatures were highly correlated (rho 0.814), and miR-16–5p, miR-142–3p, miR-223–3p and miR-451a were among the top 5 expressed miRNAs in both fractions. miR-125a-5p, miR-335–3p and miR-1260a, were detected in all lipoprotein fractions. miR-107 and miR-221–3p were uniquely detected in the VLDL fraction. HDL showed the larger number of specifically detected miRNAs (n = 13). Enrichment in specific miRNA families and genomic clusters was observed for HDL-miRNAs. Two sequence motifs were also detected for this group of miRNAs. Functional enrichment analysis including the miRNA signatures from each lipoprotein fraction suggested a potential role in mechanistic pathways previously associated with cardiovascular disease: fibrosis, senescence, inflammation, immune response, angiogenesis, and cardiomyopathy. Collectively, our results not only support the role of lipoproteins as circulating miRNA carriers but also describe for the first time the role of VLDL as a miRNA transporter., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project "Miguel Servet 2020: CP20/00041" and co-funded by the European Union. This work is supported by Instituto de Salud Carlos III (PI16/00471, PI20/00334, PI20/00577 and PI21/01523), cofunded by the European Union, IRBLleida - Fundacio ´ Dr. Pifarr´e, CERCA Programme/Generalitat de Catalunya. NR has received financial support from Ministerio de Ciencia, Innovacion ´ y Universidades (PID2019- 104367RB-100), and Agencia Estatal de Investigacion ´ (AEI/10.13039/ 501100011033) within the Subprograma Ramon ´ y Cajal (RYC201722879). CIBERDEM (CB07/08/0016), CIBERES (CB07/06/2008) and CIBERCV (CB16/11/00276) are initiatives of the Instituto de Salud Carlos III.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile

  • Rossi-Herring, Guido
  • Belmonte, Thalía
  • Rivas-Urbina, Andrea
  • Benítez, Sònia
  • Rotllan, Noemi
  • Crespo, Javier
  • Llorente-Cortés, Vicenta
  • Sánchez Quesada, Jose Luis
  • de Gonzalo Calvo, David
Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the bibliography on this topic is scarce and shows a high variability between independent investigations. In addition, the miRNA profiles of the LDL and VLDL fractions have not been completely elucidated. Here, we profiled the human circulating lipoprotein-carried miRNome. Lipoprotein fractions (VLDL, LDL and HDL) were isolated from the serum of healthy subjects by ultracentrifugation and purified by size-exclusion chromatography. A panel of 179 miRNAs commonly expressed in circulation was evaluated in the lipoprotein fractions using quantitative real-time PCR (qPCR) assays. A total of 14, 4 and 24 miRNAs were stably detected in the VLDL, LDL and HDL fractions, respectively. VLDL- and HDL-miRNA signatures were highly correlated (rho 0.814), and miR-16–5p, miR-142–3p, miR-223–3p and miR-451a were among the top 5 expressed miRNAs in both fractions. miR-125a-5p, miR-335–3p and miR-1260a, were detected in all lipoprotein fractions. miR-107 and miR-221–3p were uniquely detected in the VLDL fraction. HDL showed the larger number of specifically detected miRNAs (n = 13). Enrichment in specific miRNA families and genomic clusters was observed for HDL-miRNAs. Two sequence motifs were also detected for this group of miRNAs. Functional enrichment analysis including the miRNA signatures from each lipoprotein fraction suggested a potential role in mechanistic pathways previously associated with cardiovascular disease: fibrosis, senescence, inflammation, immune response, angiogenesis, and cardiomyopathy. Collectively, our results not only support the role of lipoproteins as circulating miRNA carriers but also describe for the first time the role of VLDL as a miRNA transporter., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project "Miguel Servet 2020: CP20/00041" and co-funded by the European Union. This work is supported by Instituto de Salud Carlos III (PI16/00471, PI20/00334, PI20/00577 and PI21/01523), cofunded by the European Union, IRBLleida - Fundacio ´ Dr. Pifarr´e, CERCA Programme/Generalitat de Catalunya. NR has received financial support from Ministerio de Ciencia, Innovacion ´ y Universidades (PID2019- 104367RB-100), and Agencia Estatal de Investigacion ´ (AEI/10.13039/ 501100011033) within the Subprograma Ramon ´ y Cajal (RYC201722879). CIBERDEM (CB07/08/0016), CIBERES (CB07/06/2008) and CIBERCV (CB16/11/00276) are initiatives of the Instituto de Salud Carlos III.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

NAD+-Increasing Strategies to Improve Cardiometabolic Health?

  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Canyelles, Marina|||0000-0002-0278-5337
  • Mauricio, Didac|||0000-0002-2868-0250
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
Depleted nicotinamide adenine dinucleotide (NAD+) is a common hallmark of metabolic disorders. Therefore, NAD+-increasing strategies have evolved as a potential therapeutic venue to combat cardiometabolic diseases. Several forms of vitamin B3, i.e., nicotinamide and nicotinamide mononucleotide, and especially nicotinamide riboside, have attracted most interest as potentially safe and efficacious candidates for NAD+ restoration. Herein, we dissected the characteristics of the latest clinical trials testing the therapeutic potential of different vitamin B3 molecules to improve cardiometabolic health, with a special focus on randomized, placebo-controlled clinical trials performed in the context of obesity or other pathologies, mainly linked to cardiovascular system and skeletal muscle functionality. The favorable outcomes via NAD+-increasing strategies found in the different studies were quite heterogeneous. NAD+-increasing interventions improved capacity to exercise, decreased blood pressure, increased the anti-inflammatory profile and insulin-stimulated glucose disposal, and reduced the fat-free mass. Except for the decreased blood pressure, the significant results did not include many hard clinical end points, such as decreases in weight, BMI, fasting glucose, or HbA1c percentage. However, the analyzed trials were short-term interventions. Overall, the accumulated clinical data can be interpreted as moderately promising. Additional and long-term studies will be needed to directly compare the doses and duration of treatments among different vitamin B3 regimes, as well as to define the type of patients, if any, that could benefit from these treatments. In this context, a major point of advancement in delineating future clinical trials would be to identify subjects with a recognized NAD+ deficiency using novel, appropriate biomarkers. Also, confirmation of gender-specific effect of NAD+-increasing treatments would be needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic Regulation by microRNAs in Hyperhomocysteinemia-Accelerated Atherosclerosis

  • Griñán, Raquel|||0000-0002-9457-3365
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Benitez, Sonia|||0000-0003-3565-0743
  • Rotllan, Noemi|||0000-0002-0587-8045
Increased serum levels of homocysteine (Hcy) is a risk factor for cardiovascular disease and is specifically linked to various diseases of the vasculature such as atherosclerosis. However, the precise mechanisms by which Hcy contributes to this condition remain elusive. During the development of atherosclerosis, epigenetic modifications influence gene expression. As such, epigenetic modifications are an adaptive response to endogenous and exogenous factors that lead to altered gene expression by methylation and acetylation reactions of different substrates and the action of noncoding RNA including microRNAs (miRNAs). Epigenetic remodeling modulates cell biology in both physiological and physiopathological conditions. DNA and histone modification have been identified to have a crucial role in the progression of atherosclerosis. However, the potential role of miRNAs in hyperHcy (HHcy)-related atherosclerosis disease remains poorly explored and might be essential as well. There is no review available yet summarizing the contribution of miRNAs to hyperhomocystein-mediated atherogenicity or their potential as therapeutic targets even though their important role has been described in numerous studies. Specifically, downregulation of miR-143 or miR-125b has been shown to regulate VSCMs proliferation in vitro. In preclinical studies, downregulation of miR-92 or miR195-3p has been shown to increase the accumulation of cholesterol in foam cells and increase macrophage inflammation and atherosclerotic plaque formation, respectively. Another preclinical study found that there is a reciprocal regulation between miR-148a/152 and DNMT1 in Hcy-accelerated atherosclerosis. Interestingly, a couple of studies have shown that miR-143 or miR-217 may be used as potential biomarkers in patients with HHcy that may develop atherosclerosis. Moreover, the current review will also update current knowledge on miRNA-based therapies, their challenges, and approaches to deal with Hcy-induced atherosclerosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The capacity of APOB-depleted plasma in inducing ATP-binding cassette A1/G1-mediated macrophage cholesterol efflux-but not gut microbial-derived metabolites-is independently associated with mortality in patients with ST-segment elevation myocardial infarction

  • Canyelles, Marina|||0000-0002-0278-5337
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Junza, Alexandra
  • Yanes, Oscar|||0000-0003-3695-7157
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sionis, Alessandro|||0000-0003-0843-9512
  • Sans-Roselló, Jordi|||0000-0003-3176-6191
  • Alquézar-Arbé, A.|||0000-0003-4164-274X
  • Santos, David|||0000-0003-1157-4969
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Impaired HDL-mediated macrophage cholesterol efflux and higher circulating concentrations of trimethylamine N-oxide (TMAO) levels are independent risk factors for cardiovascular mortality. The TMAO precursors, γ-butyrobetaine (γBB) and Trimethyllysine (TML), have also been recently associated with cardiovascular death, but their interactions with HDL-mediated cholesterol efflux remain unclear. We aimed to determine the associations between APOB depleted plasma-mediated macrophage cholesterol efflux and plasma TMAO, γBB, and TML concentrations and explore their association with two-year follow-up mortality in patients with acute ST-elevation myocardial infarction (STEMI) and unstable angina (UA). Baseline and ATP-binding cassette transporter ABCA1 and ABCG1 (ABCA1/G1)-mediated macrophage cholesterol efflux to APOB-depleted plasma was decreased in patients with STEMI, and the latter was further impaired in those who died during follow-up. Moreover, the circulating concentrations of TMAO, γBB, and TML were higher in the deceased STEMI patients when compared with the STEMI survivors or UA patients. However, after statistical adjustment, only ABCA1/G1-mediated macrophage cholesterol efflux remained significantly associated with mortality. Furthermore, neither the TMAO, γBB, nor TML levels altered the HDL-mediated macrophage cholesterol efflux in vitro. We conclude that impaired ABCA1/G1-mediated macrophage cholesterol efflux is independently associated with mortality at follow-up in STEMI patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

(r)HDL in theranostics, How do we apply HDL's biology for precision medicine in atherosclerosis management?

  • Uribe, K.B.
  • Benito-Vicente, A.
  • Martin, C.
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Rotllan, Noemi|||0000-0002-0587-8045
High-density lipoproteins (HDL) are key players in cholesterol metabolism homeostasis since they are responsible for transporting excess cholesterol from peripheral tissues to the liver. Imbalance in this process, due to either excessive accumulation or impaired clearance, results in net cholesterol accumulation and increases the risk of cardiovascular disease (CVD). Therefore, significant effort has been focused on the development of therapeutic tools capable of either directly or indirectly enhancing HDL-guided reverse cholesterol transport (RCT). More recently, in light of the emergence of precision nanomedicine, there has been renewed research interest in attempting to take advantage of the development of advanced recombinant HDL (rHDL) for both therapeutic and diagnostic purposes. In this review, we provide an update on the different approaches that have been developed using rHDL, focusing on the rHDL production methodology and rHDL applications in theranostics. We also compile a series of examples highlighting potential future perspectives in the field.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Divergent Effects of Glycemic Control and Bariatric Surgery on Circulating Concentrations of TMAO in Newly Diagnosed T2D Patients and Morbidly Obese

  • Canyelles, Marina|||0000-0002-0278-5337
  • Pérez, Antonio|||0000-0001-5528-1143
  • Junza, Alexandra
  • Miñambres, Inka|||0000-0002-0899-3938
  • Yanes, Oscar|||0000-0003-3695-7157
  • Sardà, Helena|||0000-0002-0138-8217
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
High circulating concentrations of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) are significantly associated with the risk of obesity and type 2 diabetes (T2D). We aimed at evaluating the impact of glycemic control and bariatric surgery on circulating concentrations of TMAO and its microbiota-dependent intermediate, γ-butyrobetaine (γBB), in newly diagnosed T2D patients and morbidly obese subjects following a within-subject design. Based on HbA1c concentrations, T2D patients achieved glycemic control. However, the plasma TMAO and γBB concentrations were significantly increased, without changes in estimated glomerular filtration rate. Bariatric surgery was very effective in reducing weight in obese subjects. Nevertheless, the surgery reduced plasma γBB concentrations without affecting TMAO concentrations and the estimated glomerular filtration rate. Considering these results, an additional experiment was carried out in male C57BL/6J mice fed a Western-type diet for twelve weeks. Neither diet-induced obesity nor insulin resistance were associated with circulating TMAO and γBB concentrations in these genetically defined mice strains. Our findings do not support that glycemic control or bariatric surgery improve the circulating concentrations of TMAO in newly diagnosed T2D and morbidly obese patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MiR-125b downregulates macrophage scavenger receptor type B1 and reverse cholesterol transport

  • Hueso, Miguel|||0000-0002-1824-9141
  • Griñán, Raquel|||0000-0002-9457-3365
  • Mallen, Adrián
  • Navarro, Estanislao
  • Purqueras, Elvira
  • Gomà-Gállego, Montserrat
  • Sbraga, Fabrizio
  • Blasco-Lucas, Arnau|||0000-0002-2796-7428
  • Revilla, Giovanna|||0000-0003-2971-5651
  • Santos, David|||0000-0003-1157-4969
  • Canyelles, Marina|||0000-0002-0278-5337
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rotllan, Noemi|||0000-0002-0587-8045
Objective: To determine whether miR-125b regulates cholesterol efflux in vivo and in vitro through the regulation of scavenger receptor type B1 (SR-B1). Approach and results: We demonstrated that miR-125b is up-regulated in the human aortas of patients with CAD and is located in macrophages and vascular smooth muscle cells (VSMCs). We identified SCARB1 as a direct target of miR-125b by repressing the activity of the SCARB1 3'-untranslated region reporter construct. Moreover, the overexpression of miR-125b in both human and mouse macrophages as well as VSMCs was found to downregulated the expression of the SCARB1 and the SR-B1 protein levels, thereby impairing α-HDL-mediated macrophage cholesterol efflux in vitro. The in vivo reverse cholesterol transport (RCT) rate from non-cholesterol-loaded macrophages transfected with miR-125b to feces was also found to be decreased when compared with that of control mimic-transfected macrophages. Conclusions: Together, these results provide evidence that miR-125b downregulates SCARB1 and SR-B1 in both human and mouse macrophages as well as VSMCs, thereby impairing macrophage cholesterol efflux in vitro and the whole macrophage-specific RCT pathway in vivo.